The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts

Bibliography

• Van Krogh G, Lacey CJ, Gross G, European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162-8
   PubMed Web of Science ®Google Scholar
• Health Protection Agency UK (2010). Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1215589013442
   Google Scholar
• Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8
   PubMedGoogle Scholar
• Storey A, Pim D, Murray A, Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 1988;7:1815-20
   PubMed Web of Science ®Google Scholar
• Pecoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus types 6, 16, and 18 DNAs on immortilization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 1989;86:563-7
   PubMed Web of Science ®Google Scholar
• Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs correspond to their association with cervical carcinoma. J Virol 1989;63:159-64
   PubMed Web of Science ®Google Scholar
• Gross G, Ikenberg H, Petry KU, Condylomata acuminata und other HPV-associated disease pictures of the genitals, anus and urethra. J Dtsch Dermatol Ges 2008;6:153-62
   PubMedGoogle Scholar
• Wiley DJ, Douglas J, Beutner K, External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002;35(Suppl 2):S210-24
   Google Scholar
• British association of sexual health and HIV (BASHH). UK national guideline on the management of anogenital warts, 2007. Available from: www.bashh.org/guidelines
   Google Scholar
• Centers for disease control and prevention (CDC): 2010 STD treatment guidelines. MMWR 2010;59:No RR-12. Available from: www.cdc.gov/std/treatment/2010
   Google Scholar
• AWMF-Leitlinie 059/001 Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder von Genitale, Anus und Harnrohre. Available from: http://www.awmf.org/uploads/tx_szleitlinien/059-001_S1_Condylomata_acuminata_und_andere_HPV-assoziierte_Krankheitsbilder_des_Genitale_und_der_Harnroehre_07-2006_07_2011_01.pdf
   Google Scholar
• Beutner KR, Wiley DJ. Recurrent external genital warts. a literature review. Papillomavirus Rep 1997;8:69-74
   Google Scholar
• Hara Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol Res 2011;64:100-4
   PubMed Web of Science ®Google Scholar
• VEREGEN (sinecatechins) Ointment, 15%. Available from: http://www.veregen.com/veregenrx/pdf/VER051_Promo_PI.pdf
   Google Scholar
• Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev Res (Phila) 2009;2:514-17
   PubMed Web of Science ®Google Scholar
• Ju J, Lu G, Lambert JD, Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol 2007;17:395-402
   PubMed Web of Science ®Google Scholar
• Yang CS, Wang X, Lu G, Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429-39
   PubMed Web of Science ®Google Scholar
• Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (ECGC): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011;82:1807-21
   PubMed Web of Science ®Google Scholar
• Tzellos TG, Sardeli C, Lallas A, Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta-analysis. JEADV 2011;25:345-53
   Google Scholar
• Coleman N, Birley HD, Renton AM, Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-74
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papilloma viruses. Indian J Med Res 2009;130:266-76
   PubMed Web of Science ®Google Scholar
• Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1):S7-15
   PubMed Web of Science ®Google Scholar
• Frazer IH. Interaction of human papillomaviruses with the host immune system: a well developed relationship. Virology 2009;384:410-14
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomavirus and cancer: from basic research studies to clinical application. Nat Rev Cancer 2002;2:342-50
   PubMed Web of Science ®Google Scholar
• Hoppe-Seyler F, Butz K. Cellular control of human papillomavirus oncogene transcription. Mol Carcinog 1994;10:134-41
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Munger K. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-6
   PubMed Web of Science ®Google Scholar
• Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9
   PubMed Web of Science ®Google Scholar
• Gage J, Myers C, Wettstein F. The E7 proteins of the non-oncogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma binding and other properties. J Virol 1990;64:723-30
   PubMed Web of Science ®Google Scholar
• Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin proteasome pathway. Cancer Res 1996;56:4620-4
   PubMed Web of Science ®Google Scholar
• Banerjee NS, Genovese NJ, Noya F, Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S-phase in postmitotic, differentiated human keratinocytes. J Virol 2006;80:6517-24
   PubMed Web of Science ®Google Scholar
• Genovese NJ, Banerjee NS, Broker TR, Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J Virol 2008;82:4862-73
   PubMed Web of Science ®Google Scholar
• Thomas M, Banks L. Human papillomavirus E6 interactions with Bak are conserved among E6 proteins from high and low risk HPV types. J Gen Virol 1999;80:1513-17
   PubMed Web of Science ®Google Scholar
• Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010;118:471-93
   PubMed Web of Science ®Google Scholar
• Demers GW, Foster SA, Halbert CL, Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 1994;91:4382-6
   PubMed Web of Science ®Google Scholar
• Zerfass-Thome K, Zwerschke W, Mannhardt B, Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-30
   PubMed Web of Science ®Google Scholar
• Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005;17:251-64
   PubMed Web of Science ®Google Scholar
• Li S, Labrecque S, Gauzzi MC, The human papillomavirus (HPV)-18 E6 oncoprotein physically interacts with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999;18:5727-37
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Agarwal R, Wood GS, Inhibition of 12-O-tetradecanoylphorbol-13-acetat-caused tumor promotion in 7,12-dimethybenzanthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea. Cancer Res 1992;52:6890-7
   PubMed Web of Science ®Google Scholar
• Mukthar H, Katiyar SK, Agarwal R. Green tea and skin-anticarcinogenic effects. J Invest Dermatol 1994;102:3-7
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Mohan RR, Agarwal R, Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols. Carcinogenesis 1997;18:497-502
   PubMed Web of Science ®Google Scholar
• Mittal A, Piyathilake C, Hara Y, Exceptionally high protection of photocarcinogensis by topical application of (-)-epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia 2003;5:555-65
   PubMed Web of Science ®Google Scholar
• Meeran SM, Akhtar S, Katiyar SK. Inhibition of UVB-induced skin tumor development by drinking green tea polyphenols is mediated through DNA repair and subsequent inhibition of inflammation. J Invest Dermatol 2009;129:1258-70
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Matsui MS, Elmets CA, Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem Photobiol 1999;69:148-53
   PubMed Web of Science ®Google Scholar
• Katiyar SK. Green tea prevents non-melanoma skin cancer by enhancing DNA repair. Arch Biochem Biophys 2011;508:152-8
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Nakae S, Saijo S, The roles of IL17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008;226:57-79
   PubMed Web of Science ®Google Scholar
• Katiyar SK. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:234-42
   PubMedGoogle Scholar
• Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002;42:25-54
   PubMed Web of Science ®Google Scholar
• Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from Animal Studies. J Nutr 2003;133:S3275-84
   PubMed Web of Science ®Google Scholar
• Yang GY, Liao J, Kim K, Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998;19:611-16
   PubMed Web of Science ®Google Scholar
• Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 2007;12:5039-51
   PubMed Web of Science ®Google Scholar
• Leone M, Zhai D, Sareth S, Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003;63:8118-21
   PubMed Web of Science ®Google Scholar
• Hastak K, Gupta S, Ahmad N, Role of p53 and NFkappaB in epigallocatechin-3-gallate-induced apoptosis in LNCaP cells. Oncogene 2003;22:4851-9
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421
   PubMed Web of Science ®Google Scholar
• Nomura M, Ma W, Chen N, Inhibition of 12-O-tetradecanoylphorbol-13-acetat-induced NF-kappaB activation by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavins. Carcinogenesis 2000;21:1885-90
   PubMed Web of Science ®Google Scholar
• Mauro C, Zazzeroni F, Papa S, The NFkappa B transcription factor pathway as a therapeutic target in cancer: methods for detection of NFkappa B activity. Methods Mol Biol 2009;512:169-207
   PubMedGoogle Scholar
• Gupta S, Hussain T, Mukhtar H. Molecular pathways for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003;410:177-85
   PubMed Web of Science ®Google Scholar
• Masuda M, Suzui M, Weinstein IB. Effects of epigallocartechin-3-gallate on growth, epidermal growth factor receptor signalling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001;7:4220-9
   PubMed Web of Science ®Google Scholar
• Liang YC, Lin-Shiau SY, Chen CF, Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997;67:55-65
   PubMed Web of Science ®Google Scholar
• Sah JF, Sivaprakasam B, Eckert RL, Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signalling pathway. J Biol Chem 2004;279:12755-62
   PubMed Web of Science ®Google Scholar
• Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcripts leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010;5:10. doi 10.1186/1750-2187-5-10
   PubMedGoogle Scholar
• Angel P, Karin M. The role of jun, fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57
   PubMed Web of Science ®Google Scholar
• Dong Z, Ma W, Huang C, Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea phenols (-)-epigallocatechin gallate, and theaflavins. Cancer Res 1997;57:4414-19
   PubMed Web of Science ®Google Scholar
• Cheng W, Dong Z, Valcic S, Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line. Mol Carcinog 1999;24:79-84
   PubMed Web of Science ®Google Scholar
• Yang CS, Sang S. Lambert JD, et al. bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 2008;52:S139-51
   PubMed Web of Science ®Google Scholar
• Dvorakova K, Dorr RT, Valcic S, Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. Cancer Chemother Pharmacol 1999;43:331-5
   PubMed Web of Science ®Google Scholar
• Gross G, Meyer KG, Pres H, A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. JEADV 2007;21:1404-12
   Google Scholar
• Stockfleth E, Beti H, Orasan R, Topical Polyphenon E in the Treatment of external genital and perianal warts: a randomized controlled study. Br J Dermatol 2008;158:1329-38
   PubMed Web of Science ®Google Scholar
• Tatti S, Swinehart JM, Thielert C, Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008;111:1371-9
   PubMed Web of Science ®Google Scholar
• Tatti S, Stockfleth E, Beutner KR, Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol 2010;162:176-84
   PubMed Web of Science ®Google Scholar
• Edwards L, Ferenczy A, Eron L, Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30
   PubMed Web of Science ®Google Scholar
• Beutner KR, Spruance SL, Hougham AJ, Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9
   PubMed Web of Science ®Google Scholar
• Maitland JE, Maw R. An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. Int J STD AIDS 2000;11:268-70
   PubMed Web of Science ®Google Scholar
• Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009;200:233; e1-7
   PubMed Web of Science ®Google Scholar
• Beutner KR, Conant MA, Friedman-Kien AE, Patient-applied Podofilox for treatment of genital warts. Lancet 1989;15:831-4
   Google Scholar
• Sauerbrei A, Deinhardt S, Zell R, Testing of herpes simplex virus for resistance to antiviral drugs. Virulence 2010;1:555-7
   PubMed Web of Science ®Google Scholar
• Isaacs CE, Wen GY, Xu W, Epigallocatechin gallate inactivates clinical isolates of Herpes simplex virus. Antimicrob Agents Chemother 2008;52:962-70
   PubMed Web of Science ®Google Scholar
• Nakayama M, Suzuki K, Toda M, Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res 1993;21:289-99
   PubMed Web of Science ®Google Scholar
• Song JM, Lee KW, Seong BL. Antiviral effects of catechins in green tea on influenza virus. Antiviral Res 2005;68:66-74
   PubMed Web of Science ®Google Scholar